

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[About Us](#)  
[Sloan Kettering Institute](#)  
[The Neal Rosen Lab](#)

[Research](#)

**Piro Lito**

[Education & Training](#)  
Medical Oncology Fellow

[News & Events](#)

[Open Positions](#)



**Lab Phone**

646-888-3111

## Email

[litop@mskcc.org](mailto:litop@mskcc.org)

My research is aimed at developing optimal therapies to treat cancers that harbor BRAF or KRAS mutations, as well as at understanding how these proteins affect intracellular signaling and cellular function.

## Publications

[Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Science. 2016 Feb 5;351\(6273\):604-8. doi: 10.1126/science.aad6204. Epub 2016 Jan 14.](#)

## Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Piro Lito discloses the following relationships and financial interests:

AmMax Bio, Inc.

Professional Services and Activities

Black Diamond Therapeutics, Inc.

Professional Services and Activities

Boehringer Ingelheim

Professional Services and Activities

Frontier Medicines Corporation

Equity; Professional Services and Activities

Ikena Oncology

Professional Services and Activities

OrbiMed

Professional Services and Activities

Repare Therapeutics

Professional Services and Activities

-----

## Revolution Medicines

### Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org).

[View all disclosures](#) →

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center